CBD Capital (Pharmaceuticals) is Pharmaceuticals in United Kingdom that focus on concentrated products business. Founded in 2018. They cover business area such as Wholesaler, distributor, phytocannabinoid product, internationally accredit, pharmaceutical-grade phytocannabinoid, CBD Isolates, CBD Oil, concentrate product, cbd bulk, finished good, its extraction technique, its client, quality cbd product.
2018
( 6 years old in 2024 )
Concentrated Products
-
Tavistock House, 319
Woodham Lane
Surrey KT15 3PB
England, United Kingdom
Private
Wholesalerdistributorphytocannabinoid productinternationally accredit, pharmaceutical-grade phytocannabinoidCBD IsolatesCBD Oilconcentrate productcbd bulkfinished goodits extraction techniqueits clientquality cbd product
* We use standard office opening hours in near CBD Capital (Pharmaceuticals)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
CBD Capital (Pharmaceuticals) is Pharmaceuticals business from United Kingdom that founded in 2018 (6 years old in 2024), CBD Capital (Pharmaceuticals) business is focusing on Concentrated Products.
CBD Capital (Pharmaceuticals) headquarter office and corporate office address is located in Tavistock House, 319 Woodham Lane Surrey KT15 3PB England, United Kingdom.
CBD Capital (Pharmaceuticals) was founded in United Kingdom.
In 2024, CBD Capital (Pharmaceuticals) is currently focus on concentrated products sector.
Above is snippet of Google Trends for "concentrated products" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with CBD Capital (Pharmaceuticals), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
